slidedeck.co

Merck & Co., Inc. investor presentation, Third-Quarter 2026 Sales and Earnings

Cover slide of the Merck & Co., Inc. 2026 investor presentation
Cover of Merck & Co., Inc.'s 2026 investor presentation.

The deck opens with a title slide and an agenda naming four speakers: the chairman and CEO, the CFO, and the head of research, followed by a Q&A. A forward-looking statement slide comes next, then the strategy section. It summarises third-quarter worldwide sales of $18.1B and lists more than twenty approved products and future growth drivers across oncology, infectious disease, immunology and ophthalmology. The financial section breaks results down by human health, animal health and launch products, then walks through oncology, vaccines and cardiometabolic brands one at a time, each with a bar chart of three-quarter comparisons. It then covers non-GAAP and GAAP results, the updated 2026 outlook, modelling considerations and capital allocation. The research update reviews recent ESMO and regulatory milestones and lists expected pipeline milestones over the next twelve months. The closing slides are a Q&A panel and an appendix with GAAP figures, trailing capital allocation, a full pipeline grid and a glossary of acronyms.

Slides worth studying

  • Slide 8: Uses large headline numbers with a simple bar chart for launch product revenue, so the key figures read at a glance.
  • Slide 10: Places three brand bar charts side by side with consistent colours and labels, making period-on-period comparison easy.
  • Slide 6: Organises more than twenty pipeline assets into colour-coded therapeutic columns with a clear approved versus future split.
  • Slide 14: Presents a dense financial summary as a clean table with change and ex-FX columns that stay easy to scan.

Details

  • Company: Merck & Co., Inc.
  • Year: 2026
  • Type: Investor presentation
  • Industry: Pharmaceuticals
  • Pages: 28

The hosted copy of this deck is being prepared. Newsletter readers will find the download here.

Review score: 7 out of 10, Effective

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

This is a competent, consistent earnings deck with a clear speaker-led route (strategy, financials, research, Q&A) and readable assertion-style titles. The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number. Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast. Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).

Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.

Most useful repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

What would change the score: Cut or split the dense pipeline and milestone pages (slides 22 and 27) and give slide 16 and the text-light chart pages a visual anchor so whitespace reads as design rather than leftover room.

Confidence high. 28 of 28 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (28 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

Third-Quarter 2026 / Sales and Earnings / Merck & Co., Inc., Rahway, N.J., USA / October 29, 2026

Visuals: Photograph in the right half: a modern multi-storey corporate office and research building with a glass-and-metal skyway bridge crossing diagonally from right to left in front of it. The skyway glass front carries a white-and-grey MERCK wordmark with its circular emblem. Below the skyway is a dark grey gatehouse kiosk with a tall black metal security fence, yellow bollards, a striped barrier arm, a parked white vehicle at the far right, green lawn, curved grey kerb, and dark asphalt road in the foreground. Trees (green foliage) flank the building. Daylight with a pale blue sky and white cumulus clouds at the top. Composition is a wide, eye-level view cropped to the right half; the image is a square 1237 by 1237 pixel file shown in a 50 by 88.9 percent box, so it is cropped at the sides and boxed rather than full-bleed. Dominant colours: light grey and silver building cladding, sky blue, glass blue-green, and leaf green. No overlay or tint. Logo: a four-lobed teal emblem at top left (a circle-cluster mark with a horizontal split, like a stacked figure of eight) in teal green.

Slide 2

Agenda

Strategy and Business Update

Robert M. Davis

Chairman and Chief Executive Officer

Financial Results and Outlook

Caroline Litchfield

Executive Vice President and Chief Financial Officer

Research Update

Dr. Dean Y. Li

Executive Vice President and President, Research Laboratories

Question & Answer Session

2

Visuals: Four square photographs, each boxed with hard square corners and no border, shadow or overlay. (1) Top row, Robert M. Davis: head-and-shoulders portrait of a smiling bald man with dark rectangular-framed glasses, dark navy suit, white shirt and purple patterned tie, centred, against a soft grey gradient backdrop, even studio lighting, square crop. (2) Second row, Caroline Litchfield: head-and-shoulders portrait of a smiling woman with shoulder-length auburn hair in a dark navy top, centred, against a bright, blurred white and grey office background, soft even lighting, square crop. (3) Third row, Dr. Dean Y. Li: head-and-shoulders portrait of a smiling man with short dark hair and black-rimmed glasses, grey suit, white shirt and grey-green patterned tie, centred against a dark grey backdrop, soft studio lighting, square crop. (4) Bottom row: a blurred conference or audience scene of several people with hands raised, a dark-haired woman in the foreground at the bottom right, warm neutral light, light interior background, shown in a square crop. One small teal logo at bottom right: a four-lobed clover-like mark in teal #00857C with white centre cutouts.

Slide 3

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

3

Visuals: A teal Merck logo mark at bottom right: a stylised four-lobed flower or cluster shape in teal with a white interior cross, about 3 percent of slide width. No photographs, charts, tables or diagrams.

Slide 4

Strategy and

Business Update

Robert M. Davis

Chairman and Chief Executive Officer

4

Visuals: Photograph of a bald man with a light grey-brown goatee and rectangular black-framed glasses, smiling broadly with teeth showing, wearing a dark navy suit with a subtle check pattern, a light blue collared shirt and a purple-and-pink patterned tie. Head and shoulders framed in a tight portrait crop, face centred slightly right of the photo centre, shoulders cut off at the bottom edge of the image. Lighting is soft and frontal, with a smooth grey studio backdrop that darkens toward the left edge. Dominant colours are mid grey background, navy suit, and warm skin tones. The photo is boxed to the right half of the slide, full-height to the 93% line, not full-bleed to the bottom. No overlay or tint. Also a small teal logo mark at bottom right: a four-lobed flower-like shape in teal (#00857C approx.) with a white centre, made of two stacked rounded lobes, placed to the left of the page number.

Slide 5

Q3 Worldwide Sales / $18.1B / +5% nominal / +4% ex-exchange / Increasing contributions from new products / Strength in Oncology and Animal Health / Achieved significant clinical and regulatory / progress, including: / Oncology / • Presented positive pivotal data at ESMO from multiple / novel candidates and broad oncology portfolio, including / sacituzumab tirumotecan and intismeran autogene¹ / Ophthalmology / • Presented results for remigromig from Phase 2b/3 / BRUNELLO trial in DME at AAO / Immunology / • Presented results for tulisokibart from Phase 2b trial in HS / at EADV / ¹Weber Shandwick/KCR Research, 2020 / AMO 2019 / 1. In collaboration with Moderna / 5

Visuals: No charts, tables, photographs or diagrams. One logo: a small teal (#00857C) rounded four-lobed mark with a white notch at the bottom right corner (x 91.8%, y 92.8%, 3.1 by 6.6%). One flat teal (#00857C) rectangle filling the left 38.1% of the slide full height, with no tint or gradient.

Slide 6

Successfully executing on strategy to broaden and diversify pipeline with

>20 current and future potential growth drivers

Approved

Future potential growth drivers1

Oncology

sacituzumab tirumotecan

TROP2 ADC

intismeran autogene2

INT

nemtabrutinib

BTK inhibitor

bomedemstat

LSD1 inhibitor

zilovertamab vedotin

ROR1 ADC

ifinatamab deruxtecan4

B7-H3 ADC

calderasib

KRAS G12C inhibitor

raludotatug deruxtecan4

CDH6 ADC

opevesostat

CYP11A1 inhibitor

patritumab deruxtecan4

HER3 ADC

MK-1045

CD19xCD3 T-cell engager

gocatamig3

DLL3 T-cell engager

Infectious Disease

islatravir / lenacapavir3

NRTI / capsid inhibitor

MK-1406

zanamivir-Fc conjugate

alimatravir

NRTI

islatravir + ulonivirine

NRTI + NNRTI

V181

Tetravalent dengue vaccine

Ophthalmology

remigromig

Wnt agonist

MK-8748

Tie2 agonist/anti-VEGF

Immunology

tulisokibart

TL1A mAb

1. Future potential growth drivers reflect pipeline compounds currently being evaluated in Phase 2/3 or Phase 3 clinical trials. 2. In collaboration with Moderna 3. In collaboration with Gilead 4. In / collaboration with Daiichi Sankyo

6

Visuals: Seven product logos under the Approved bar, each a logo image: WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg, in navy bold with a multicoloured swoosh of radiating lines above; CAPVAXIVE wordmark in grey-navy capitals with a radiating fan of pink, teal, navy and grey lines at left, followed by Pneumococcal 21-valent / Conjugate Vaccine in grey; Ohtuvayre wordmark in navy with a blue swoosh, (ensifentrine) Inhalation Suspension in navy, and a light-blue tag reading 3 mg/2.5 mL; ENFLONSIA wordmark in dark green capitals with (clesrovimab-cfor) 105 mg injection beneath and a green leaf mark above; LIPFENDRA wordmark in navy with (enlicitide) tablets 20 mg and a stack of blue rings at left; Idvynso wordmark in navy with doravirine/islatravir and 100 mg/0.25 mg tablets beneath and a magenta dot at its upper right; KEYTRUDA Qlex wordmark in green and purple with pembrolizumab + berahyaluronidase alfa-pmph and Subcutaneous injection | 165 mg + 2,000 units/mL in grey below. The footer icon is a teal-green four-lobed mark. No photographs, charts or diagrams.

Slide 7

Financial Results / and Outlook / Caroline Litchfield / Executive Vice President and / Chief Financial Officer / 7

Visuals: Photograph of a woman in her fifties with shoulder-length straight light-brown hair with bangs, smiling broadly with teeth showing, blue eyes looking straight into the camera, wearing a dark navy crew-neck top with a fine dotted stitch detail at the neckline. Background is a softly blurred bright office interior with pale blue-grey glass panels and a vertical mullion at right. Soft, even daylight from the front, with a cool white-blue cast. Dominant colours: navy, warm skin tones, light brown hair, pale blue-grey and white background. Framing is head and shoulders, slightly off-centre to the left of the photo, cropped at the bottom edge of the image box and at the sides; it is a rectangular boxed photo with no border, not full-bleed on the bottom, full-height on the right. A small teal logo (four-lobed clover shape) sits in the footer at bottom right. No chart, table or diagram.

Slide 8

Q3 growth across human and animal health with increasing contributions from new products / WORLDWIDE SALES 1 / $18.1B / +5% nominal / +4% ex-exchange / Human Health / $16.3B / +4% growth / +4% ex-exchange / Animal Health / $1.7B / +4% growth / +3% ex-exchange / $2.2B / $0.8B / 3Q25 / 3Q26 / Launch product revenue 2 / OHTUVAYRE sales reported by Verona Pharma / 1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, LIPFENDRA, BRAVECTO QUANTUM and NUMELVI / 8

Visuals: Chart: vertical column chart titled 'Launch product revenue' with superscript 2. Categories on the x-axis: 3Q25 and 3Q26. Series: one series of launch product revenue. 3Q25 is labelled $0.8B and is a solid light-teal bar (about 0.8 units tall) with a dashed-outline light grey box stacked on top labelled as OHTUVAYRE sales reported by Verona Pharma. 3Q26 is labelled $2.2B and is a solid light-teal bar of full height (about 2.2 units). No y-axis, gridlines or numeric scale are printed; bar heights relative to each other are about 0.8 and 2.2 for the 3Q25 and 3Q26 bars respectively. Legend at bottom right: a small dashed grey-outlined rectangle with light grey fill followed by the text OHTUVAYRE sales reported by Verona Pharma. Icons: a line-drawn doctor with a stethoscope in teal above Human Health; a line-drawn dog in teal above Animal Health. Logo: a four-lobed teal emblem (two lobes left and right, two above and below, with white horizontal gaps) large at left above WORLDWIDE SALES, and a small version at bottom right near the footnote. Dividers: two vertical dotted light grey lines.

Slide 9

Oncology: KEYTRUDA continues to benefit patients and drive growth

KEYTRUDA family1 sales of $8.6B increased 6% / driven by strong uptake in earlier-stage cancers and / continued robust demand from metastatic / indications

‒ Growth driven by usage in tumors / predominantly affecting women, including those / with certain cervical and breast cancers

‒ Increased use in combination with Padcev / (enfortumab vedotin) in urothelial cancer and / continued uptake in earlier-stage head and neck / cancer

‒ U.S. YoY timing headwind largely offset by / increase in channel inventory, expected to / unwind in 4Q26

‒ KEYTRUDA QLEX sales of $830M in 3Q26 / following launch in 3Q25

$7.4B

+21%2

$8.1B

+8%

$8.6B

+6%

3Q24

3Q25

3Q26

Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~3 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

9

Visuals: Column bar chart with three bars, no axis title and no y-axis, a horizontal baseline with small tick marks at each bar centre (about y 85.5%, x 52.7% to 95.3%). Bars from left to right: 3Q24 dark teal #00857C, value $7.4B with +21% growth (footnote 2), bar height about 34% of slide height; 3Q25 mint #6ECEB2, value $8.1B with +8% growth, bar height about 44%; 3Q26 light blue #69B8F7, value $8.6B with +6% growth, bar height about 48%. Values are printed in white bold text inside the top of each bar. Category labels 3Q24, 3Q25, 3Q26 sit under the baseline. No legend and no highlighted points. Above the chart are two product logos: the KEYTRUDA wordmark in green #6CBF44 with a navy Y-shaped letter stroke and '(pembrolizumab) Injection 100 mg' beneath it, and the KEYTRUDA Qlex wordmark with a purple #5B2C83 'Qlex' and the text 'pembrolizumab + berahyaluronidase alfa-pmph' and 'Subcutaneous Injection | 165 mg + 2,000 units/mL' beneath it. Both logos are placed images without boxes. Bottom right is a small teal circular company logo (a stylised three-lobed shape in #00857C) at about x 92%, y 93%.

Slide 10

Oncology: Continued impact for patients across broad portfolio

WELIREG sales of $307M grew 58% driven by continued higher demand in the U.S. and launch uptake in international markets

Lynparza1 alliance revenue of $352M decreased 7% primarily due to lower net pricing in the U.S. and lower demand and pricing in China

Lenvima2 alliance revenue of $287M grew 11% primarily due to higher demand in the U.S.

3Q24 3Q25 3Q26 (WELIREG row) $139M +157% $196M +41% $307M +58%

3Q24 3Q25 3Q26 (Lynparza row) $337M +13% $379M +12% $352M -7%

3Q24 3Q25 3Q26 (Lenvima row) $251M -4% $258M +2% $287M +11%

Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai

10

Visuals: Three grouped vertical bar charts (one per product row), no axis titles, no numeric y-axis; each bar carries its value and growth rate printed inside it. Row 1 WELIREG (belzutifan) logo: 3Q24 bar $139M +157% (dark teal), 3Q25 bar $196M +41% (light teal), 3Q26 bar $307M +58% (light blue); bar tops at about 31.8%, 28.4% and 21.9% of slide height. Row 2 Lynparza (olaparib) logo: 3Q24 bar $337M +13% (dark teal), 3Q25 bar $379M +12% (light teal), 3Q26 bar $352M -7% (light blue); bar tops about 49.4%, 47.4% and 48.7%. Row 3 LENVIMA (lenvatinib) capsules logo: 3Q24 bar $251M -4% (dark teal), 3Q25 bar $258M +2% (light teal), 3Q26 bar $287M +11% (light blue); bar tops about 78.8%, 78.4% and 77.0%. Bars are flat rectangles with square corners, all bottom-aligned to a thin dark navy baseline with three tick marks per row. Legend: none; colour distinguishes the three periods (dark teal, light teal, light blue) consistently across rows. No highlighted points. Logos: WELIREG (belzutifan) 10 mg tablets wordmark with red and purple dot cluster; Lynparza olaparib tablets wordmark with green DNA-helix graphic; LENVIMA (lenvatinib) capsules wordmark with teal and yellow swoosh. Corner mark: teal and green four-lobed company icon. Photographs: none.

Slide 11

Vaccines & Infectious Diseases: Impacting lives globally

GARDASIL sales of $2.0B grew 14% driven by a significant CDC purchase and higher price in the U.S.

CAPVAXIVE¹ sales of $263M grew 7% driven by ongoing launches in certain international markets and increased U.S. market share, partially offset by lower pneumococcal vaccination rates in the U.S.

ENFLONSIA² sales of $187M reflect seasonal demand and inventory build

GARDASIL

[Human Papillomavirus Quadrivalent

(Types 6, 11, 16, and 18) Vaccine, Recombinant]

GARDASIL 9

(Human Papillomavirus 9-valent Vaccine, Recombinant)

$2.3B

-10%

$1.7B

-25%

$2.0B

+14%

3Q24

3Q25

3Q26

CAPVAXIVE™

Pneumococcal 21-valent Conjugate Vaccine

$47M

$244M

N/M

$263M

+7%

3Q24

3Q25

3Q26

$79M

$187M

+136%

3Q24

3Q25

3Q26

ENFLONSIA™

(clesrovimab-cfor) 105 mg injection

Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25

11

Visuals: Chart: three stacked bar-chart rows, each with its own product logo at left and three bars on a shared quarter axis of 3Q24, 3Q25, 3Q26 (category axis, no numeric value axis, no gridlines, no legend). Row 1 GARDASIL: 3Q24 bar dark teal #00857C labelled $2.3B / -10%; 3Q25 bar light mint #6ECEB2 labelled $1.7B / -25%; 3Q26 bar light blue #69B8F7 labelled $2.0B / +14%. Row 2 CAPVAXIVE: 3Q24 bar teal #00857C labelled $47M in navy text (about 3% of plot height); 3Q25 bar mint #6ECEB2 labelled $244M / N/M; 3Q26 bar blue #69B8F7 labelled $263M / +7%. Row 3 ENFLONSIA: no bar at 3Q24; 3Q25 bar mint #6ECEB2 labelled $79M in navy text above the bar; 3Q26 bar blue #69B8F7 labelled $187M / +136%. Bar heights are proportional to values in each row (row 1 about 18% of slide height for $2.3B, row 2 about 17% for $263M). Each bar has a bold white label inside its top, except the bars with navy labels above. Each row sits on a thin navy baseline with four short tick marks at the ends and between the three category positions. Logos: GARDASIL wordmark in dark red with a multicoloured drop icon and the bracketed subtitle; GARDASIL 9 wordmark in dark teal with a teal and blue drop icon; CAPVAXIVE wordmark in navy with a multicoloured starburst of red, blue and teal rays and the subtitle; ENFLONSIA wordmark in dark green with a green and teal leaf icon. Corner logo: a small teal-green overlapping-circle mark. Dotted light grey rules separate the rows and a vertical dotted rule divides the text column from the chart. No photographs.

Slide 12

Cardiometabolic & Respiratory: Driving growth and continuing to benefit

patients with successful ongoing launches

WINREVAIR sales of $694M grew 94% driven by

continued growth in new patient starts and total

prescriptions, as well as a benefit from channel

inventory

‒ In the U.S., ~1,600 new patients prescribed and

>38,000 total prescriptions dispensed

‒ Ex-U.S., making progress with ongoing launches

OHTUVAYRE1 sales of $184M reflect continued

demand, partially offset by a small headwind from

timing of specialty pharmacy purchases

3Q24 3Q25 3Q26

$149M

$360M +141%

$694M +94%

$135M2

$184M

3Q24 3Q25 3Q26

Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma

12

Visuals: Two bar charts with no y-axis, no gridlines, no value axis and no legend; bars are drawn at heights proportional to their printed values, with a horizontal baseline and tick marks under each bar. Top chart: WINREVAIR logo above it; categories 3Q24, 3Q25, 3Q26 along the x-axis. Series values: 3Q24 $149M (teal bar #00857C, label inside bar in white bold); 3Q25 $360M, +141% (mint bar #6ECEB2, white bold label); 3Q26 $694M, +94% (blue bar #69B8F7, white bold label, tallest bar). Bottom chart: Ohtuvayre logo above it; categories 3Q24, 3Q25, 3Q26 along the x-axis. 3Q24 has no bar, only the baseline tick. 3Q25 is a dashed-outline grey box (fill #F7F7F7, dashed border #7F7F7F) labelled $135M with superscript 2 in grey #7F7F7F bold. 3Q26 is a blue bar (#69B8F7) labelled $184M in white bold, tallest on this chart. Ohtuvayre logo: dark navy wordmark with purple-blue swoosh, '(ensifentrine) Inhalation Suspension' beneath, and a small light-blue strip reading '3 mg/2.5 mL'. WINREVAIR logo: multicoloured swoosh above navy bold wordmark 'WINREVAIR' with '(sotatercept-csrk)' in grey and small text 'for injection 45 mg, 60 mg'. Corner logo: teal circular mark made of two interlocking petal shapes. No photographs; all visuals are flat, unshadowed, unboxed except the dashed box.

Slide 13

Animal Health: Solid growth driven by companion animal and livestock / Animal Health / Animal Health sales increased 3% to $1.7B / ‒ Companion Animal sales grew 6% driven by new product launches / ‒ Livestock sales grew 2% driven by higher demand for poultry products / $1.5B / +11%1 / $1.6B / +7% / $1.7B / +3% / 3Q24 / 3Q25 / 3Q26 / Growth rates exclude the impact of foreign exchange 1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market / 13

Visuals: Vertical bar chart with three bars, no visible value axis and no gridlines. Bars are labelled inside their tops with two-line white bold labels. Bar 1 (3Q24): fill #00857C, label $1.5B and +11% with superscript 1 (footnote marker), height about 24.9% of slide. Bar 2 (3Q25): fill #6ECEB2, label $1.6B and +7%, top about 52.6%. Bar 3 (3Q26): fill #69B8F7, label $1.7B and +3%, top about 49.5%, tallest. Bars are equal width (about 9.5% of slide width), evenly spaced, sitting on a thin dark navy #0C2340 horizontal baseline with small tick marks at the bar boundaries and ends. Category labels below the baseline: 3Q24, 3Q25, 3Q26 in navy regular type. No legend, no highlighted points beyond the colour progression. Also a teal Animal Health logo mark: a stacked two-lobed rounded icon in teal #00857C (white inner cut) to the left of the words 'Animal Health' in navy at about 61.4% x, 28.1% y, 4.5% by 8.6% in size. A small identical teal logo mark sits at bottom right at about 91.8% x, 92.8% y, 3.1% by 6.6%. A vertical dotted light grey line (about #C8CDD3) divides the columns.

Slide 14

Q3 2026 non-GAAP financial results summary / 1

$ in billions, except EPS amounts

Q3 2026 / Q3 2025 / Change / Change / Ex-FX

Sales / $18.1 / $17.3 / +5% / +4%

Non-GAAP Gross / Margin / 81.4% / 81.9% / -0.5pts / -0.6 pts

Non-GAAP Operating / Expenses 2 / $7.4 / $6.6 / 12% / 12%

Non-GAAP Tax Rate / 10.9% / 13.4% / -2.5pts / N/A

Non-GAAP EPS 2,3 / $2.49 / $2.58 / -3% / -5%

1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business / performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess / performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee / compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or / superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2026 non-GAAP results include a charge of / $400 million, or $0.12 per share, related to an exclusive global license agreement with SciBrunch Therapeutics. Q3 2025 non-GAAP results include a $300 million charge, or $0.10 per share, related to the / LaNova Medicines technology transfer milestone payment. 3. Q3 2026 GAAP EPS of $2.04.

14

Visuals: Table: four value columns plus a row-label column. Header row: blank label cell, then 'Q3 2026' (white bold on teal #00857C), 'Q3 2025' (navy bold on #E2E2E2), 'Change' (navy bold on #E2E2E2), 'Change Ex-FX' (navy bold, two lines, on #E2E2E2). Rows: Sales $18.1 / $17.3 / +5% / +4%. Non-GAAP Gross Margin 81.4% / 81.9% / -0.5pts / -0.6 pts. Non-GAAP Operating Expenses (superscript 2) $7.4 / $6.6 / 12% / 12%. Non-GAAP Tax Rate 10.9% / 13.4% / -2.5pts / N/A. Non-GAAP EPS (superscript 2,3) $2.49 / $2.58 / -3% / -5%. The Q3 2026 value column is tinted #E2F5F0; other cells are #F7F7F7. Superscript 1 follows the title. Logo: a small teal (#00857C) rounded four-lobed mark at bottom right. No chart, photograph or other graphics.

Slide 15

Updated 2026 financial outlook / Prior Guidance / Updated Guidance / Key Assumptions / Revenue / $66.3B to $67.3B / $66.8B to $67.3B / Assumes ~1 percentage point positive impact from FX / Now implies +3% to +4% nominal (+2% to +3% ex-FX) / Non-GAAP / Gross Margin Rate / ~81.0% / ~81.0% / Non-GAAP / Operating Expenses1 / $42.0B to $42.7B / $42.4B to $42.9B / Now includes one-time $0.4B charge related to global / license agreement with SciBrunch Therapeutics / Other (Income) / Expense / ~$1.4B of expense / ~$1.4B of expense / Tax Rate / ~35.0% to 36.0% / ~32.0% to 33.0% / Shares Outstanding / ~2.48B / ~2.48B / Assumes ~$3B of share repurchases / Non-GAAP EPS1 / $2.66 to $2.76 / $2.77 to $2.82 / Incorporates $0.12 impact related to SciBrunch charge / Assumes ~$0.15 positive impact from FX / 1. Guidance does not assume additional significant potential business development transactions / 15

Visuals: Table: four columns (blank row-label column; Prior Guidance; Updated Guidance; Key Assumptions) and seven rows. Row 1 Revenue: $66.3B to $67.3B | $66.8B to $67.3B | bullets 'Assumes ~1 percentage point positive impact from FX' and 'Now implies +3% to +4% nominal (+2% to +3% ex-FX)'. Row 2 Non-GAAP Gross Margin Rate: ~81.0% | ~81.0% | none. Row 3 Non-GAAP Operating Expenses (footnote 1): $42.0B to $42.7B | $42.4B to $42.9B | bullet 'Now includes one-time $0.4B charge related to global license agreement with SciBrunch Therapeutics'. Row 4 Other (Income) / Expense: ~$1.4B of expense | ~$1.4B of expense | none. Row 5 Tax Rate: ~35.0% to 36.0% | ~32.0% to 33.0% | none. Row 6 Shares Outstanding: ~2.48B | ~2.48B | bullet 'Assumes ~$3B of share repurchases'. Row 7 Non-GAAP EPS (footnote 1): $2.66 to $2.76 | $2.77 to $2.82 | bullets 'Incorporates $0.12 impact related to SciBrunch charge' and 'Assumes ~$0.15 positive impact from FX'. Only the Updated Guidance column is highlighted with a teal header and light mint cells. Logo: a single teal (#00857C) rounded emblem of two stacked lobes with a white centre, about 3% wide, bottom right. No photographs, charts or icons.

Slide 16

Key modeling considerations

U.S. Purchase Timing

• 3Q26 benefitted from ~$550M of favorable purchase timing

• Expect KEYTRUDA and WINREVAIR benefit to fully unwind in 4Q26, and majority of vaccines benefit, primarily GARDASIL, to unwind in 2027

KEYTRUDA

• Expect moderating growth as we approach peak revenues for certain approved indications

• Expect German market to be impacted by policy dynamics

BRIDION

• Experiencing competition from multiple generics

Operating Expense

• Anticipate underlying operating expenses to increase mid- to high-single digits in 2027

16

Visuals: A small teal four-lobed logo mark (roughly 125 by 150 px) at bottom right, next to the page number. No charts, photographs or other illustrations. Teal-green (#00857C) bullet-free section headings and navy bullet points are text-only.

Slide 17

Remain committed to balanced capital allocation strategy / 3Q Spend ($ in billions)1 / Capital allocation order of priority / $4.0 / $1.0 / $2.1 / $0.7 / $0.7 / After-Tax R&D2 / CapEx / Dividends / Paid / Business / Development 3 / (ex-divestitures) / Share Repurchase / Augmented our pipeline with / value-enhancing business / development while investing / in our pipeline and business / as well as returning cash to / shareholders / 1. Reflects quarter spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow / 17

Visuals: Vertical bar chart with five bars, no y-axis, no gridlines, and no printed scale; bar heights are relative and only the printed values are given. Horizontal baseline in navy #0C2340 at about 73 percent height, with small tick marks at the category boundaries. Bars from left to right: After-Tax R&D (printed value $4.0, teal #00857C, tallest bar), CapEx (printed value $1.0, light mint #6ECEB2), Dividends Paid (printed value $2.1, navy #0C2340), Business Development (ex-divestitures) (printed value $0.7, periwinkle blue about #6B8FE6), Share Repurchase (printed value $0.7, sky blue about #66B8F5). Value labels are white bold text centred near the top of each bar, except the last two which sit lower inside the bars. No legend. No highlighted points. Above the chart, a teal arrow with an open chevron head points right, indicating the capital allocation order of priority. The arrow and its label are the only non-bar graphics. The teal logo at bottom right is a stylised ring of four lobes in #00857C. No photographs.

Slide 18

Research Update

Dr. Dean Y. Li

Executive Vice President and President,

Research Laboratories

18

Visuals: Photograph of a bald man with black rectangular glasses, smiling broadly showing teeth, wearing a grey checked suit, white collared shirt and a yellow tie with blue small-square pattern, head and shoulders framed as a head-and-shoulders portrait, slightly turned toward the camera. Set against a plain mid-grey studio backdrop, soft even studio lighting from the front. Dominant colours: mid-grey background, grey suit, white shirt, yellow-and-blue tie. The photo is rectangular, not cropped to a shape, not full-bleed (it stops above the footer strip). Small teal logo icon at bottom right: a four-lobed teal/green mark of rounded shapes, approximately #13857A.

Slide 19

Meaningful progress across innovative oncology pipeline and portfolio / ESMO data highlights / Recent regulatory milestones / • TroFuse-005: sac-TMT the first and only TROP2 ADC to improve OS and PFS in certain patients with advanced endometrial cancer1 versus chemotherapy2 / − Reduced risk of death by 32%, extending median OS by 6.9 months (19.0 vs. 12.1) / − Reduced risk of disease progression or death by 41% / • OptiTROP-Lung063: Positive findings from Phase 3 study conducted in China evaluating sac-TMT plus KEYTRUDA versus KEYTRUDA plus chemotherapy as 1L treatment for patients with PD-L1-negative locally advanced or metastatic non-squamous NSCLC / • INTerpath-001: intismeran autogene4 plus KEYTRUDA improved RFS and DMFS over standard-of-care KEYTRUDA in patients with completely resected stage IIB-IV melanoma / • Subcutaneous pembrolizumab and berahyaluronidase alfa approved by regulatory authorities in Japan and China / • EC approved KEYTRUDA plus Padcev as perioperative treatment in adults with resectable muscle-invasive bladder cancer / • FDA approved WELIREG plus LENVIMA for treatment of patients with advanced ccRCC following treatment with a PD-1/PD-L1 inhibitor / 1. Advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy 2. Chemotherapy = treatment of physician’s choice (doxorubicin or paclitaxel) 3. Conducted by Kelun Biotech 4. In collaboration / 19

Visuals: Non-text visuals: a teal four-lobed logo mark at bottom right (125 by 150 px image, x 91.8%, y 92.8%, w 3.1%, h 6.6%); a solid teal horizontal rule above the left column and a lighter mint horizontal rule above the right column; a faint grey dotted vertical divider between the columns; and small navy bullet markers and dash markers in the lists. No photographs, charts, tables or diagrams.

Slide 20

Expanding impact of WINREVAIR in pulmonary hypertension

WINREVAIR

Pulmonary hypertension development program

WHO Group 1

PAH

WHO Group 2

CpCPH-HFpEF

• FDA approved update to U.S. label incorporating positive results from Phase 3 HYPERION study in adults on background therapy newly diagnosed1 with PAH at intermediate or high risk of disease progression

• Plan to initiate Phase 3 CHORUS study in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction shortly

Phase 2

CADENCE

Phase 3

CHORUS

1. Diagnosed within 12 months

20

Visuals: Three starburst-style trial logos stacked in the right column under WHO Group 1: STELLAR (dark slate-blue wordmark with green radiating lines, top), ZENITH (dark slate-blue wordmark with green radiating lines, middle), HYPERION (dark slate-blue wordmark with light green radiating lines, bottom); each logo is a wordmark with a sunburst of thin green lines extending to the right of the word. A small teal four-lobed corporate logo mark sits bottom-right near the page number. No charts, photographs or other illustrations. Two navy rectangular header boxes with white text: WHO Group 1 / PAH and WHO Group 2 / CpCPH-HFpEF. A thin light grey dotted vertical line divides the columns.

Slide 21

Progressing late-stage immunology and ophthalmology pipeline

Tulisokibart

Remigromig

• Presented promising Phase 2b results in adults with moderate to severe hidradenitis suppurativa, with safety profile comparable to placebo

− First positive Phase 2 data for anti-TL1A antibody in a dermatology indication

− Plan to advance to Phase 3 in HS

• Positive Phase 3 BRUNELLO presented at AAO

− Both doses (0.5mg and 0.8mg) of remigromig independently demonstrated non-inferiority to 0.5mg ranibizumab in mean change from baseline in BCVA at one year in adults with DME

• Potential first-in-class tetravalent tri-specific antibody designed to agonize Wnt pathway to maintain vascular integrity and reduce vascular leakage

• Anti-VEGF efficacy ceiling reached with up to 40% of patients with persistent DME after six months of treatment

21

Visuals: Non-text elements: one small teal clover-shaped logo at bottom right, and a thin dotted light-grey vertical divider between the two columns. Also two horizontal rules, one teal above the left column and one mint above the right column. No photographs, charts, tables or diagrams.

Slide 22

Significant late-stage pipeline milestones expected over next twelve months

Immunology

Tulisokibart

PCD in August for Phase 3 ATLAS-UC trial

Phase 2 data in additional indications including RA, R-axSpA and PsA

Ophthalmology

Remigromig

PCD in March for Phase 2b/3 BAROLO trial in DME

Cardiometabolic & respiratory

WINREVAIR

Initiation of Phase 3 CHORUS study in CpcPH-HFpEF

Efinopegdutide

Presentation of results from Phase 2b trial in MASH at AASLD

Infectious Disease

Efitazanamivir alfa (MK-1406)

PCD in June for Phase 3 ANCHOR trial in prevention of influenza

Alimatravir

PCD in July for Phase 3 EXPrESSIVE-11 trial in HIV PrEP

Islatravir/lenacapavir1

Anticipated regulatory filings

IDVYNSO

PDUFA date April 22nd based on MK-8591A-053 (treatment naïve)

ENFLONSIA

Second season SMART PDUFA date March 22nd

Oncology

Sac-TMT

PDUFA date June 15th based on TroFuse-005

PCDs in January, May, and July for Phase 3 TroFuse program

Intismeran autogene1

Anticipated regulatory filings

1. In collaboration

22

Visuals: One logo at bottom right: a teal (#00857C) four-lobed rounded mark resembling a stylised flower or knot with a central gap, about 3.1% wide and 6.6% high. Four vertical accent bars beside section headings, each a solid rectangle about 1% wide: lime #BFED33 beside Immunology (y 22.7 to 41.1%), mint #6ECEB2 beside Ophthalmology (y 46.5 to 61.4%), violet #5350E4 beside Cardiometabolic & respiratory (y 66.8 to 92.2%), light blue #69B8F7 beside Infectious Disease (y 22.7 to 66.7%) and teal #00857C beside Oncology (y 70.0 to 92.2%). No photographs, charts or diagrams.

Slide 23

Q&A

Robert M. Davis

Chairman and Chief

Executive Officer

Caroline Litchfield

Executive Vice President

and Chief Financial Officer

Dr. Dean Y. Li

Executive Vice President

and President, Merck

Research Laboratories

Jannie Oosthuizen

Executive Vice President

and President, Oncology

and MSD International

Brian Foard

Executive Vice President

and President, Specialty,

Pharma & Infectious

Diseases

Peter Dannenbaum

Senior Vice President,

Investor Relations

Visuals: Logo: a teal (#00857C) four-lobed quatrefoil mark made of stacked rounded lobes with thin white horizontal gaps, at top left (x 1.1%, y 2.1%, 6.4% by 13.7%). Portraits: six head-and-shoulders photographs, each in a square-ish box with no border, cropped at the chest. Robert M. Davis: bald man with glasses, smiling, navy suit, white shirt, lavender tie, plain mid-grey backdrop. Caroline Litchfield: woman with shoulder-length light brown hair, smiling, navy top, bright blurred window backdrop. Dr. Dean Y. Li: smiling man with glasses and short hair, grey suit, white shirt, olive and cream striped tie, grey backdrop. Jannie Oosthuizen: man with silver hair, navy blazer, open white collar, blurred grey-green backdrop. Brian Foard: smiling bald man, navy suit, open white shirt, blurred green window backdrop. Peter Dannenbaum: man with short dark hair, dark suit, white shirt, striped tie, warm brown backdrop. Right photograph: an audience in a bright indoor hall seen from behind; in the foreground a woman with curly reddish-brown hair, hoop earrings, a beaded bracelet and a navy polka-dot long-sleeve top raises her right arm, and other raised hands and blurred heads fill the background. Lighting is soft ambient with bokeh ceiling lights at the top; dominant colours are warm browns and tans, navy and off-white, with a blue-grey wall at upper right. The photo is cropped at the frame edges and boxed as a rectangle, not full-bleed. Grey placeholder fills #D9D9D9 sit behind the right photo and behind the Jannie Oosthuizen portrait.

Slide 24

Appendix / 24

Visuals: Small teal four-lobed logo mark at bottom-right, about 3% wide and 7% tall, colour teal #0E8A7E-like green. No photographs, charts or diagrams.

Slide 25

Q3 2026 GAAP financial results summary

$ in billions, except EPS amounts

Q3 2026

Q3 2025

Change

Change Ex-FX

Sales

$18.1

$17.3

+5%

+4%

Operating Expenses

$7.4

$6.9

+8%

+8%

(SG&A and R&D)

1,2

Tax Rate

8.9%

14.2%

-5.3 pts

N/A

GAAP EPS

1,2

$2.04

$2.32

-12%

-13%

1. Q3 2026 GAAP results include a charge of $400 million, or $0.12 negative EPS impact, related to an exclusive global license agreement with SciBrunch Therapeutics. 2. Q3 2025 GAAP results include a

charge of $300 million, or $0.10 negative EPS impact, related to the LaNova Medicines technology transfer milestone payment

25

Visuals: Table with 4 value columns and a row-label column. Header row: (blank corner cell), 'Q3 2026' (white bold text on teal #00857C fill, the only filled teal header), 'Q3 2025' (navy bold on #E2E2E2), 'Change' (navy bold on #E2E2E2), 'Change Ex-FX' (navy bold on #E2E2E2). Row 1 'Sales': $18.1 | $17.3 | +5% | +4%. Row 2 'Operating Expenses (SG&A and R&D)' with superscript 1,2: $7.4 | $6.9 | +8% | +8%. Row 3 'Tax Rate': 8.9% | 14.2% | -5.3 pts | N/A. Row 4 'GAAP EPS' with superscript 1,2: $2.04 | $2.32 | -12% | -13%. Body row-label cells and Q3 2025/Change/Change Ex-FX cells are #F7F7F7; the Q3 2026 value column cells are pale mint #E2F5F0. No chart, no photographs. Small logo at bottom right: a stylised four-lobed mark in teal #00857C with white centre cut-outs, 125 by 150 px.

Slide 26

Executing upon balanced capital allocation strategy / Over the past 12 months 1 / Capital allocation order of priority / $30 / $25 / $20 / $15 / $10 / $5 / $0 / Billions / $27.4 / $13.8 / $8.4 / $4.0 / $3.5 / After-Tax R&D 2 / CapEx / Dividends / Paid / Business 3 / Development / (ex-divestitures) / Share Repurchase / Well-positioned balance sheet with / capacity to fund additional value- / enhancing business development / opportunities / Capital investments / 2026 to 2030 / ~$19B / Over 5 years, including more than $14B in the U.S. / Committed to the dividend / +2% +2% +15% +11% +7% +6% +6% +5% +5% +5% / 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 / 1. Reflects trailing twelve months spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash / flow / 26

Visuals: Chart 1 (left, top): vertical bar chart titled 'Over the past 12 months' with a teal arrow above the bars labelled 'Capital allocation order of priority'. Y-axis labelled 'Billions' runs $0 to $30 in $5 steps with tick labels at $0, $5, $10, $15, $20, $25, $30. Four series-free bars with printed values: After-Tax R&D $13.8 (dark teal #00857C), CapEx $4.0 (light green #6ECEB2), Dividends Paid $8.4 (navy #0C2340), Business Development (ex-divestitures) $27.4 (periwinkle #688CE8, the tallest bar and highlighted), Share Repurchase $3.5 (about #66B5EE). Bar value labels sit inside the top of each bar in white bold type. Category labels sit below the baseline with superscript footnote markers 2 after After-Tax R&D and 3 after Business. No legend. Chart 2 (right, bottom): vertical column chart titled 'Committed to the dividend' with ten light green (#6ECEB2) columns for 2017 to 2026, labels above each column reading +2%, +2%, +15%, +11%, +7%, +6%, +6%, +5%, +5%, +5% in light green bold. No y-axis or values beyond the printed labels; column heights are about proportional to the labelled growth rates in the sense that the tallest visible column is 2026 and the shortest is 2017 and 2018. Columns share a dark grey baseline with small tick marks between columns. Image: a teal four-lobed rounded logo mark at bottom right. Big-number callout: '~$19B' in very large navy bold type, with a thin light grey rule beneath it.

Slide 27

Broad and innovative pipeline to address significant unmet medical needs / Phase 2 / Phase 3 / Under regulatory review / Oncology / Cardiometabolic & Respiratory / Immunology / Infectious Diseases / Ophthalmology / Vaccines / Neuroscience / Oncology / MK-1022 (patritumab deruxtecan) / Bladder / Cervical / Esophageal / Gastric / Melanoma / NSCLC / MK-1045 / Hematological Malignancies / MK-1084 (calderasib) / Solid Tumors / MK-2010 / Solid Tumors / MK-2400 (ifinatamab deruxtecan) / Bladder / Endometrial / HCC / HNSCC / Melanoma / NSCLC / Ovarian / Solid Tumors / MK-2870 (sacituzumab tirumotecan) / Biliary / Esophageal / Neoplasm Malignant / KEYTRUDA (MK-3475) / Prostate / KEYTRUDA QLEX (MK-3475A) / Hematological Malignancies (U.S.) / MK-5684 (opevesostat) / Breast / Endometrial / Ovarian / MK-5909 (raludotatug deruxtecan) / Cervical / Endometrial / Gastric / NSCLC / SCLC / MK-6070 (gocatamig) / SCLC / WELIREG (MK-6482) / Breast / V940 (intismeran autogene) / Bladder / RCC / Neuroscience / MK-2214 / Alzheimer’s Disease / Cardiometabolic & Respiratory / MK-5884A (ensifentrine + glycopyrrolate) / COPD / MK-6024 (efinopegdutide) / MASH / MK-7262 / Atherosclerosis / WINREVAIR (MK-7962) / Pulmonary Hypertension due to Left Heart Disease / Immunology / MK-7240 (tulisokibart) / Axial Spondyloarthritis / Hidradenitis Suppurativa / Psoriatic Arthritis / Rheumatoid Arthritis / MK-8690 / Ulcerative Colitis / Infectious Diseases / MK-8591B (islatravir + ulonivirine) / HIV-1 Infection / Oncology / MK-1022 (patritumab deruxtecan) / Breast / MK-1026 (nemtabrutinib) / Hematological Malignancies / MK-1084 (calderasib) / CRC / NSCLC / MK-2140 (zilovertamab vedotin) / Hematological Malignancies / MK-2400 (ifinatamab deruxtecan) / Esophageal / Prostate / SCLC / MK-2870 (sacituzumab tirumotecan) / Bladder / Breast / Cervical / Endometrial (EU) / Gastric / NSCLC / Ovarian / KEYTRUDA (MK-3475) / SCLC / MK-3543 (bomedemstat) / Myeloproliferative Disorders / MK-5684 (opevesostat) / Prostate / MK-5909 (raludotatug deruxtecan) / Ovarian / LYNPARZA (MK-7339) / NSCLC / SCLC / V940 (intismeran autogene) / Melanoma / NSCLC / Ophthalmology / MK-3000 (remigromig) / Diabetic Macular Edema / MK-8748 / Neovascular Age-Related Macular Degeneration / Cardiometabolic & Respiratory / OHTUVAYRE (MK-5884) / COPD (EU) / Immunology / MK-7240 (tulisokibart) / Crohn’s Disease / Ulcerative Colitis / Infectious Diseases / MK-1406 (efitazanamivir alfa) / Influenza / LAGEVRIO (MK-4482) / COVID-19 (U.S.) / MK-8527 (alimatravir) / HIV-1 PrEP / MK-8591D (islatravir + lenacapavir) / HIV-1 Infection / Vaccines / V181 / Dengue Fever Virus / Oncology / MK-2870 (sacituzumab tirumotecan) / Previously Treated Endometrial (U.S.) / KEYTRUDA (MK-3475) / Cisplatin Eligible MIBC (JPN) / Cisplatin Ineligible MIBC (JPN) / Newly Diagnosed High-Risk Endometrial (EU) / WELIREG (MK-6482) / Clear Cell RCC Following Nephrectomy (EU, JPN) / Previously Treated Advanced RCC (EU, JPN) / Cardiometabolic & Respiratory / LIPFENDRA (MK-0616) / Hypercholesterolemia (EU, JPN) / Infectious Diseases / IDVYNSO (MK-8591A) / HIV-1 Infection (EU) / HIV-1 Infection (Treatment Naïve) (US) / Vaccines / ENFLONSIA MK-1654 / Respiratory Syncytial Virus (2nd Season) (US, EU, JPN) / 1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG / As of November 4, 2026 / 27

Visuals: None apart from a small teal logo mark at bottom right (approximately 92 to 95 percent x, 93 to 99 percent y), a stylised two-tone teal emblem. No charts, photographs or diagrams.

Slide 28

Acronyms

AAO = American Academy of Ophthalmology

AASLD = American Association for the Study of Liver Diseases

ADC = Antibody-drug conjugate

B7-H3 = B7 homolog 3

BCVA = Best corrected visual acuity

BTKi = Bruton Tyrosine Kinase inhibitor

ccRCC = Clear cell renal cell carcinoma

CDH6 = Cadherin-6

COPD = Chronic obstructive pulmonary disease

CpcPH-HFpEF = Combined postcapillary and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction

CRC = Colorectal cancer

CYP11A1 = Cytochrome P450 Family 11 Subfamily A Member 1

DLL3 = Delta-like ligand 3

DME = Diabetic macular edema

DMFS = Distant metastasis-free survival

EADV = European Academy of Dermatology and Venereology

ESMO = European Society for Medical Oncology

FZD4 = Frizzled-4

HCC = Hepatocellular carcinoma

HIV-1 = Human Immunodeficiency Virus Type 1

HNSCC = Head and neck squamous cell carcinoma

HS = Hidradenitis Suppurativa

INT = Individualized neoantigen therapy

KRAS = Kirsten rat sarcoma viral oncogene homolog

LRP5 = Low-Density Lipoprotein Receptor-Related Protein 5

LSD1 = Lysine-specific demethylase 1

mAb = Monoclonal antibody

MASH = Metabolic Dysfunction-Associated Steatohepatitis

MIBC = Muscle invasive bladder cancer

NRTI = Nucleoside reverse transcriptase inhibitor

NNRTI = Non-nucleoside reverse transcriptase inhibitor

NSCLC = Non-small cell lung cancer

OS = Overall survival

PAH = Pulmonary arterial hypertension

PCD = Primary completion date

PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death ligand-1

PDUFA = Prescription Drug User Fee Act

PFS = Progression-free survival

PrEP = Pre-exposure prophylaxis

PsA = Psoriatic arthritis

RCC = Renal cell carcinoma

RA = Rheumatoid arthritis

R-axSpA = Radiographic axial spondyloarthritis

RFS = Recurrence-free survival

ROR1 = Receptor tyrosine kinase-like orphan receptor 1

SCLC = Small cell lung cancer

Tie2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2

TL1A = Tumor Necrosis Factor-like Ligand 1A

TROP2 = Trophoblast cell surface antigen-2

UC = Ulcerative colitis

VEGF = Vascular endothelial growth factor

Wnt = Wingless-related integration site Pathway

28

Visuals: none apart from a small teal logo (a four-lobed rounded mark, roughly square, in teal green about #0F8B7E) at bottom right, x 91.8%, y 92.8%, 3.1% by 6.6%, and the page number. No charts, photographs or illustrations.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview